Foundational guide
Glutathione Injection Dosage Chart: Reading the Indication Field
Forty-seven registered studies and a substantial literature, almost none of it addressing the indication the search demand is about. The mismatch is the finding.
Most entries on this site fail on volume: there is not enough evidence to grade. Glutathione fails differently and more interestingly. There is plenty of evidence, it is of reasonable quality, and it is about something other than the question being asked.
That makes the indication field, rather than the phase, the one that decides how any figure should be read.
The portfolio, and what it studies
| Phase | Studies |
|---|---|
| Not applicable | 17 |
| Phase 2 | 11 |
| Phase 3 | 6 |
| Phase 1 | 5 |
| Phase 4 | 4 |
| Phase 1/2 | 3 |
| Early Phase 1 | 1 |
Roughly 47 records in total. The subject matter is chemotherapy-resistant ovarian cancer, advanced hepatocellular carcinoma, male infertility and related clinical questions. Titles mentioning skin, whitening, lightening or pigmentation number about two.
Grading against the question actually asked
A phase label describes how far a study went, not what it went after. Six Phase 3 records is a strong portfolio, and it is a strong portfolio about liver disease and cancer.
Graded against the cosmetic indication that drives nearly all the search demand, the registered record supplies almost nothing, and that is a finding rather than an absence of one. A glutathione injection dosage chart that names the study, the population and the route behind each figure makes the mismatch visible. One that prints quantities alone conceals it perfectly.
Route, and the endogenous argument
Intravenous, intramuscular and subcutaneous administration are not interchangeable, and each registered protocol selected one for its own reasons. A figure carried across routes has changed exposure before it changed anything else.
The other argument encountered constantly is that glutathione is endogenous and therefore safe to supplement freely. Tight physiological regulation of a molecule is a reason to want evidence about exogenous administration, not a substitute for having it.
Frequently asked questions
- What evidence tier applies to cosmetic glutathione injection?
- Effectively none from the registered record. Of roughly 47 studies, about two mention skin, whitening or pigmentation in the title, so the indication most searches concern is close to unrepresented.
- Is the wider glutathione literature strong?
- Yes. Over twelve thousand PubMed records mention the molecule, and the registered injection studies span Phase 1 to Phase 4 in oncology, hepatology and reproductive medicine.
- Why does the indication field matter more than the phase here?
- Because a Phase 3 study establishes something about the population and endpoint it enrolled. A high phase in hepatocellular carcinoma says nothing about a cosmetic outcome in a healthy person.
- Does route affect how a figure transfers?
- Substantially. Intravenous, intramuscular and subcutaneous administration produce different exposure, and the trials selected a route for their own question.
- Does endogenous production reduce the need for evidence?
- No. Tight endogenous regulation is a reason to require evidence for an exogenous dose, not a reason to assume safety.
Limitations of the evidence
This page grades provenance and prints no administration guidance. No approval exists for injected glutathione for cosmetic or skin-lightening purposes in any market examined here. The registered literature addresses oncology, hepatology and reproductive medicine, and quantities drawn from those protocols carry no read-across to cosmetic use, a different population and frequently a different route. Material sold outside a pharmacy carries a seller's claim about its labelled mass rather than an assay. Nothing here describes or recommends human use.